Biofrontera Inc. (NASDAQ:BFRI) Shares Shorted: Short Interest Up 83.8% in October

Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 189,627 shares, an increase of 83.8% from the October 15th total of 103,148 shares. Based on an average daily trading volume, of 146,358 shares, the short-interest ratio is presently 1.3 days. Approximately 1.4% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BFRI shares. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Biofrontera from a “buy” rating to a “hold” rating in a research report on Sunday, September 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Biofrontera in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Check Out Our Latest Analysis on BFRI

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its stake in Biofrontera stock. AIGH Capital Management LLC increased its holdings in Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 102.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,496,583 shares of the company’s stock after purchasing an additional 756,673 shares during the period. AIGH Capital Management LLC owned approximately 10.08% of Biofrontera worth $1,616,000 as of its most recent SEC filing. 10.08% of the stock is currently owned by institutional investors and hedge funds.

Biofrontera Stock Performance

Shares of NASDAQ BFRI opened at $0.70 on Monday. The stock has a market cap of $10.40 million, a price-to-earnings ratio of -2.80 and a beta of 0.88. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.78. Biofrontera has a 1-year low of $0.55 and a 1-year high of $1.66. The stock’s 50-day moving average is $1.02 and its 200 day moving average is $1.03.

Biofrontera (NASDAQ:BFRI – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.31). The firm had revenue of $9.07 million during the quarter, compared to the consensus estimate of $8.50 million. Biofrontera had a negative return on equity of 97.59% and a negative net margin of 12.72%.

About Biofrontera

(Get Free Report)

Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market. The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin. Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure.

See Also

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.